Jul 2026
Integrated multiomics profiling reveals MS-specific molecular signatures linked to progression and response to nasal anti-CD3 (Foralumab) therapy 2267524
It is found that nasal Foralumab ameliorates MS by increasing TGFB1 and suppressing T cell cytotoxicity and inflammation and found that nasal Foralumab ameliorates MS by increasing TGFB1 and suppressing T cell cytotoxicity and inflammation.
Ronaldo S. Francisco, Thais G. Moreira, Patrick da Silva et al.
· Journal of Immunology · 0 citations